Porton Completes Acquisition of J-STAR Research
CRANBURY, N.J., Wednesday April 5th, 2017—Porton Fine Chemicals, Ltd., (“Porton”, SZ 300363), a China-based contract development and manufacturing organization （CDMO） serving the global pharmaceutical industry, today announced that Porton USA, L.L.C. (“PTC”), a wholly-owned subsidiary of Porton, has closed the previously announced transcation with the shareholders of J-STAR Research, Inc. (“J-STAR”), a contract chemistry organization based in South Plainfield, New Jersey. The strategic acquisition will complement Porton’s recently launched Process Technology Center in Cranbury, NJ and adds J-STAR’s expertise and technologies onto more comprehensive, integrated development services to more customers.
Founded in 2005, Porton Fine Chemicals is a top-tier, China-based external manufacturing partner and strategic supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to many of the world’s leading pharmaceutical companies.
We own and operate three Process technology centers and three manufacturing sites across China, including a US FDA-approved site. Supported by more than 1,700 customer-oriented employees, including more than 500 process scientists, operations, quality assurance, EHS and program management professionals, our sites are operated to global quality and environmental standards under a centralized management system.
For more information, please visit http://www.porton.cn/.